N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
Cancer Cell2016Vol. 30(4), pp. 563–577
Citations Over TimeTop 1% of 2016 papers
Étienne Dardenne, Himisha Beltran, Matteo Benelli, Kaitlyn Gayvert, Adeline Berger, Loredana Puca, Joanna Cyrta, Andrea Sboner, Zohal Noorzad, Theresa Y. MacDonald, Cynthia Cheung, Ka Shing Yuen, Dong Gao, Yu Chen, Martin Eilers, Juan‐Miguel Mosquera, Brian D. Robinson, Olivier Elemento, Mark A. Rubin, Francesca Demichelis, David S. Rickman
Related Papers
- → The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER‐positive breast cancers(2014)61 cited
- → EZH2-Activating Mutations in DLBCL Are Easily Predictable by Routine Immunohistochemistry Analysis: a Tool to More Efficiently Define EZH2 Inhibitor-Sensitive Patients?(2015)
- The Prognostic Significance of Neuroendocrine Differentiation for Treating Prostatic Carcinoma in 699 Cases of Radical Prostatectomy(2008)
- → Histone methyltransferase EZH2 in the pathogenesis of lymphoma(2019)
- → [Research Progress of Expression and Clinical Significant of EZH2 in Hematological Malignancies--Review].(2020)